KEY POINTS
- This preclinical study from MD Anderson Cancer Center investigated whether ultrahigh-dose-rate FLASH radiotherapy could preserve lymphocytes while maintaining immunogenic signaling in HPV-positive tumors. Experiments used TC-1 and mEER murine cancer cell lines and syngeneic C57BL/6 mice bearing subcutaneous mEER tumors, comparing conventional dose-rate irradiation with FLASH delivery using a 9-MeV electron accelerator.
- In vivo treatment delivered 27 Gy in three consecutive daily fractions of 9 Gy, with mean dose rates of approximately 270 Gy/s for FLASH versus 0.2 Gy/s for conventional RT. Tumors, peripheral blood and tumor-draining lymph nodes were collected two days after the final fraction, allowing assessment of early immunological changes rather than long-term tumor response or survival.
- In HPV-positive TC-1 cells, FLASH increased expression of several immunogenic signaling markers, including calreticulin (CALR), HMGB1 and components of the cGAS–STING pathway, compared with conventional irradiation. At 9 Gy, HMGB1 expression was 4.17-fold versus 0.97-fold relative to sham, while STING expression was 2.2-fold versus 0.9-fold (both p<0.001). Responses were less consistent in mEER cells, and TC-1 clonogenic survival did not differ significantly between dose rates (p=0.87).
- FLASH was associated with greater preservation of lymphocytes in tumor-draining lymph nodes. Mean absolute CD8+ T-cell counts were 1.7 × 10⁴ versus 0.8 × 10⁴ with conventional RT (p<0.001), while CD4+ T-cell counts were 2.3 × 10⁴ versus 1.2 × 10⁴ (p<0.001). Lymphocyte numbers after FLASH approached those observed in nonirradiated control mice.
- The lymphocyte-sparing association extended to functionally relevant T-cell subsets. In tumor-draining nodes, effector-like CD8+ T cells increased from 0.5 × 10³ after conventional RT to 2.2 × 10³ after FLASH (p<0.001), while corresponding effector-like CD4+ T cells increased from 3.3 × 10³ to 11 × 10³ (p<0.01). These differences suggest greater preservation of antigen-experienced lymphocytes during the early post-irradiation period.
- Multiplex immunofluorescence showed substantially greater intratumoral immune-cell infiltration after FLASH. CD8+ T-cell density was 57.4 versus 16.7 cells/mm² after conventional RT (p<0.05), representing approximately 3.4-fold higher infiltration. However, the proportion of PD-1-positive CD8+ cells increased from 6.2% to 31.0%, and PD-L1-positive tumor-associated macrophages increased from 0.54% to 11.3% (both p<0.05), indicating simultaneous preservation of potentially immunosuppressive checkpoint signaling.
- The findings therefore suggest a complex immune response rather than uniformly enhanced antitumor immunity. Greater lymphocyte preservation and immunogenic-marker expression coexist with increased PD-1/PD-L1 signaling, raising a hypothesis for combining FLASH with checkpoint inhibitors. However, checkpoint blockade was not tested, and the study did not measure long-term tumor control, survival or clinical toxicity; immune profiling was largely limited to a single early time point in subcutaneous murine tumors.
CLINICAL TAKEAWAY
FLASH irradiation may influence antitumor immunity beyond conventional normal-tissue sparing, preserving lymphocyte populations while increasing immune infiltration and immunogenic signaling in HPV-positive preclinical models. The simultaneous increase in PD-1/PD-L1 expression suggests a possible rationale for combination strategies, but these observations remain mechanistic and do not establish improved tumor control, immunotherapy synergy or clinical benefit.